Moxonidine (INN) is a new-generation centrally acting antihypertensive drug licensed for the treatment of mild to moderate essential hypertension. It may have a role when thiazides, beta-blockers, ACE inhibitors and calcium channel blockers are not appropriate or have failed to control blood pressure. In addition, it demonstrates favourable effects on parameters of the insulin resistance syndrome, apparently independent of blood pressure reduction. It is manufactured by Solvay Pharmaceuticals under the brand name Physiotens.

CAS：75438-57-2
中文别名：莫索尼定,不带盐酸;4-氯-N-(4,5-二氢-1H-咪唑-2-基)-6-甲氧基-2-甲基-5-嘧啶胺;莫索尼定;
英文别名：Lomox;Norcynt;[14C]-Moxonidine;4-chloro-5-[(4,5-dihydro-1H-imidazol-2-yl)-amino]-6-methoxy-2-methylpyrimidine;Moxonidinum [Latin];4-chloro-5-(imidazoline-2-ylamino)-6-methoxy-2-methylpyrimidine;BE 5895;Moxonidine;Cynt;MOXONIDINE;Nucynt;Physiotens;4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine;4-chloro-N-(4,5-dihydro-1H9imidazol-yl)-6-methoxy-2-methyl-5-pyrimidinamine;Normoxocin;[3H]-Moxonidine;
分子式：C9H12ClN5O
分子量：241.677
精确质量：241.073
Psa：71.43
Logp：0.6555

MDL号：MFCD22689455

外观与性状：晶体
密度：1.52 g/cm3 (20ºC)
沸点：364.7ºC at 760 mmHg
熔点：40-43°C(lit.)
闪点：>230°F
折射率：1.68
储存条件：Store in original container in a cool dark place.

RTECS号：UV6260290
WGK Germany：3

生产方法
方法1:5-氨基-4,6-二氯-2-甲基嘧啶和1-乙酰基-2-咪唑啉-2-酮反应,生成的产物和甲醇钠作用得莫索尼定。 通过刺激中枢突触前α2-受体而起效。其降压效果和钙拮抗剂硝苯地平和ACE抑制剂卡托普利相似。用于原发性高血压。
用途
通过刺激中枢突触前α2-受体而起效。其降压效果和钙拮抗剂硝苯地平和ACE抑制剂卡托普利相似。用于原发性高血压。